Why did adjusted EPS decline so sharply despite revenue growth?

Revenue grew 12%, but the benefit expense ratio rose 180 basis points to 91.3% due to elevated Medicare cost trend, particularly Part D seasonality. Health Benefits margin fell to 1.4%, and adjusted operating expense rose 100 basis points on investments in Carelon, workforce, and technology. Adjusted diluted EPS fell to $6.03 from $8.60.

Is the company still on track to meet its full-year 2025 guidance?

Yes, management reaffirmed the FY 2025 benefit expense ratio of approximately 90.0% and adjusted diluted EPS of approximately $30.00. Year-to-date adjusted EPS is $26.88, so the guidance implies roughly $3.12 of adjusted EPS in the fourth quarter, a meaningful step-up from the third quarter's $6.03 that investors should scrutinize.

What is driving growth at Carelon and how does it offset Health Benefits pressure?

Carelon revenue rose 33% to $18.3 billion from acquisitions in home health and pharmacy, CarelonRx product revenue growth, and scaling of Carelon Services risk-based solutions. Carelon operating gain held at $0.8 billion, providing a partial offset, though its margin also narrowed to 4.2% from 5.8%.

How is Elevance managing its capital and cash flow?

Year-to-date operating cash flow was $4.2 billion, down $0.9 billion, partly due to a Provider Settlement Agreement payment for BCBSA multi-district litigation. The company repurchased 2.9 million shares for $875 million in the quarter, paid $381 million in dividends, and had about $2.6 billion of cash and investments at the parent company.

What are the main risks to watch going into 2026?

Key risks include medical cost trend in Medicare, particularly Part D under the Inflation Reduction Act; continued Medicaid membership losses from eligibility reverifications; Medicare and Medicaid regulatory and Star Ratings exposure; litigation costs; and goodwill impairment risk given $39.8 billion of goodwill and intangibles. Management also flagged its substantial debt of roughly $31.9 billion as a factor in its risk disclosures.

ELV 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 21, 2025. Cited figures are marked; the original filing is the authoritative source.

Elevance Health (ELV) reported third quarter 2025 results on October 21, 2025, with headline revenue growth strong but profitability under clear pressure.

Operating revenue rose 12.0% year over year to $50.1 billion^a, driven by higher premium yields, recent acquisitions (notably in home health and pharmacy services at Carelon), and Medicare Advantage membership growth, partially offset by Medicaid membership losses from eligibility reverifications. GAAP diluted EPS was $5.32, up 22.0%, but adjusted diluted EPS fell to $6.03 from $8.60 a year earlier, a 29.9% decline, reflecting a sharp deterioration in the core Health Benefits business. The benefit expense ratio rose 180 basis points to 91.3%, driven by elevated medical cost trend concentrated in Medicare Part D, and the Health Benefits operating margin compressed to 1.4% from 4.2%.

Segment mix shifted meaningfully. Health Benefits operating gain fell 62.5% to $0.6 billion^b, while Carelon's operating revenue grew 33% to $18.3 billion and its operating gain held roughly flat at $0.8 billion, with Carelon Services and CarelonRx showing solid year-to-date growth. Management highlighted disciplined execution, AI-enabled digital solutions, and value-based care partnerships, and characterized third quarter results as in line with expectations.

Adjusted operating expense ratio rose 100 basis points to 10.4% due to targeted investments in Carelon capabilities, workforce, and technology, even as GAAP operating expense ratio improved. From a capital perspective, the company reaffirmed its full-year 2025 guidance of approximately 90.0% benefit expense ratio and approximately $30.00^c adjusted diluted EPS. Year-to-date operating cash flow was $4.2 billion, down $0.9 billion, reflecting a Provider Settlement Agreement payment tied to BCBSA multi-district litigation.

The company returned $3.3 billion^d to shareholders year to date, repurchased $875 million of stock in the quarter, declared a $1.71 quarterly dividend, and retained about $7.2 billion of buyback authorization. Investors should weigh the reaffirmed guidance against a third quarter that implies a steep second-half earnings ramp, and monitor Medicare cost trends and Medicaid membership attrition heading into 2026 planning.

02—Key points

Key Highlights

Operating revenue of $50.1 billion, up 12.0% year over year, driven by premium yield increases, acquisitions, and Medicare Advantage growth.
GAAP diluted EPS of $5.32 (up 22.0%) versus adjusted diluted EPS of $6.03, down 29.9% from $8.60 in the prior-year quarter.
Benefit expense ratio rose 180 basis points to 91.3%, reflecting elevated Medicare cost trend tied to Part D seasonality under the Inflation Reduction Act.
Health Benefits operating margin compressed to 1.4% from 4.2%, with operating gain down 62.5% to $0.6 billion.
Carelon operating revenue grew 33% to $18.3 billion, with operating gain steady at $0.8 billion amid platform investments.
FY 2025 guidance reaffirmed: benefit expense ratio of approximately 90.0% and adjusted diluted EPS of approximately $30.00.
Returned $3.3 billion to shareholders year to date; $7.2 billion of share repurchase authorization remains, and a $1.71 quarterly dividend was declared.

03—Questions

Frequently Asked Questions

Why did adjusted EPS decline so sharply despite revenue growth?
Revenue grew 12%, but the benefit expense ratio rose 180 basis points to 91.3% due to elevated Medicare cost trend, particularly Part D seasonality. Health Benefits margin fell to 1.4%, and adjusted operating expense rose 100 basis points on investments in Carelon, workforce, and technology. Adjusted diluted EPS fell to $6.03 from $8.60.
Is the company still on track to meet its full-year 2025 guidance?
Yes, management reaffirmed the FY 2025 benefit expense ratio of approximately 90.0% and adjusted diluted EPS of approximately $30.00. Year-to-date adjusted EPS is $26.88, so the guidance implies roughly $3.12 of adjusted EPS in the fourth quarter, a meaningful step-up from the third quarter's $6.03 that investors should scrutinize.
What is driving growth at Carelon and how does it offset Health Benefits pressure?
Carelon revenue rose 33% to $18.3 billion from acquisitions in home health and pharmacy, CarelonRx product revenue growth, and scaling of Carelon Services risk-based solutions. Carelon operating gain held at $0.8 billion, providing a partial offset, though its margin also narrowed to 4.2% from 5.8%.
How is Elevance managing its capital and cash flow?
Year-to-date operating cash flow was $4.2 billion, down $0.9 billion, partly due to a Provider Settlement Agreement payment for BCBSA multi-district litigation. The company repurchased 2.9 million shares for $875 million in the quarter, paid $381 million in dividends, and had about $2.6 billion of cash and investments at the parent company.
What are the main risks to watch going into 2026?
Key risks include medical cost trend in Medicare, particularly Part D under the Inflation Reduction Act; continued Medicaid membership losses from eligibility reverifications; Medicare and Medicaid regulatory and Star Ratings exposure; litigation costs; and goodwill impairment risk given $39.8 billion of goodwill and intangibles. Management also flagged its substantial debt of roughly $31.9 billion as a factor in its risk disclosures.

04—Continue

← View all 8-K filings